Phase II Study of Bortezomib Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 17 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 02 Dec 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 02 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.